Crossmark

Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics

Crossref DOI link: https://doi.org/10.1186/s12920-025-02173-w

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Chenfan

Wang, Pandeng

Huang, Diemei

Guo, Jianji

Liu, Tao
Funding

Funding for this research was provided by:

Natural Science Foundation of Guangxi Zhuang Autonomous Region (2022JJA140162, 2022JJA140162, 2022JJA140162, 2022JJA140162, 2022JJA140162)
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 14 February 2025

Accepted: 29 May 2025

First Online: 1 July 2025

Declarations

:

: This study was approved by the Ethics Committee of Guangxi International Zhuang Medicine Hospital approved the study protocol(No.2023-065-01).Informed consent was obtained from participants for the participation in the study and all methods were carried out in accordance with the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below